Charles River Laboratories International, Inc. CRL
We take great care to ensure that the data presented and summarized in this overview for CHARLES RIVER LABORATORIES INTERNATIONAL, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CRL
View all-
Vanguard Group Inc Valley Forge, PA6.16MShares$1 Billion0.02% of portfolio
-
Black Rock Inc. New York, NY5.09MShares$829 Million0.02% of portfolio
-
Wellington Management Group LLP Boston, MA4.08MShares$665 Million0.14% of portfolio
-
State Street Corp Boston, MA2.18MShares$356 Million0.02% of portfolio
-
Allspring Global Investments Holdings, LLC1.81MShares$295 Million0.56% of portfolio
-
Kayne Anderson Rudnick Investment Management LLC Los Angeles, CA1.81MShares$294 Million0.79% of portfolio
-
Geode Capital Management, LLC Boston, MA1.23MShares$201 Million0.02% of portfolio
-
Impactive Capital LP New York City, NY1.2MShares$196 Million9.54% of portfolio
-
Nat Simons Meritage Group LP | San Francisco, Ca1.07MShares$175 Million5.41% of portfolio
-
Ariel Investments, LLC Chicago, IL1.07MShares$174 Million2.33% of portfolio
Latest Institutional Activity in CRL
Top Purchases
Top Sells
About CRL
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Insider Transactions at CRL
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Feb 20
2025
|
James C Foster Chairman, President and CEO |
BUY
Open market or private purchase
|
Direct |
6,075
+3.2%
|
$1,002,375
$165.01 P/Share
|
Feb 20
2025
|
Joseph W La Plume EVP, Corp Strategy & Develop |
SELL
Open market or private sale
|
Direct |
4,400
-18.02%
|
$712,800
$162.5 P/Share
|
Feb 20
2025
|
Birgit Girshick Corporate Executive VP & COO |
BUY
Open market or private purchase
|
Direct |
1,514
+2.68%
|
$248,296
$164.63 P/Share
|
Jan 31
2025
|
Flavia Pease Corporate Executive VP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
914
-7.33%
|
$150,810
$165.57 P/Share
|
Jan 31
2025
|
Flavia Pease Corporate Executive VP & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
2,704
+17.83%
|
-
|
Jan 31
2025
|
James C Foster Chairman, President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,827
-3.34%
|
$1,126,455
$165.57 P/Share
|
Jan 31
2025
|
James C Foster Chairman, President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
19,608
+8.75%
|
-
|
Jan 31
2025
|
Joseph W La Plume EVP, Corp Strategy & Develop |
SELL
Payment of exercise price or tax liability
|
Direct |
846
-3.35%
|
$139,590
$165.57 P/Share
|
Jan 31
2025
|
Joseph W La Plume EVP, Corp Strategy & Develop |
BUY
Grant, award, or other acquisition
|
Direct |
2,738
+9.78%
|
-
|
Jan 31
2025
|
Shannon M Parisotto CEVP, Disc & Safety Assessment |
SELL
Payment of exercise price or tax liability
|
Direct |
471
-4.97%
|
$77,715
$165.57 P/Share
|
Jan 31
2025
|
Shannon M Parisotto CEVP, Disc & Safety Assessment |
BUY
Grant, award, or other acquisition
|
Direct |
1,758
+15.66%
|
-
|
Jan 31
2025
|
Victoria L Creamer EVP & Chief People Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
791
-4.57%
|
$130,515
$165.57 P/Share
|
Jan 31
2025
|
Victoria L Creamer EVP & Chief People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,468
+12.49%
|
-
|
Jan 31
2025
|
Michael Gunnar Knell CSVP&Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
282
-3.09%
|
$46,530
$165.57 P/Share
|
Jan 31
2025
|
Michael Gunnar Knell CSVP&Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
811
+8.15%
|
-
|
Jan 31
2025
|
Birgit Girshick Corporate Executive VP & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,025
-1.88%
|
$169,125
$165.57 P/Share
|
Jan 31
2025
|
Birgit Girshick Corporate Executive VP & COO |
BUY
Grant, award, or other acquisition
|
Direct |
4,057
+6.92%
|
-
|
Nov 08
2024
|
James C Foster Chairman, President and CEO |
SELL
Bona fide gift
|
Direct |
4,500
-2.38%
|
-
|
Nov 07
2024
|
Richard F Wallman Director |
SELL
Open market or private sale
|
Indirect |
1,000
-100.0%
|
$216,000
$216.5 P/Share
|
Nov 07
2024
|
Richard F Wallman Director |
SELL
Open market or private sale
|
Direct |
6,621
-19.26%
|
$1,430,136
$216.13 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 54K shares |
---|---|
Open market or private purchase | 7.59K shares |
Payment of exercise price or tax liability | 17.2K shares |
---|---|
Bona fide gift | 12.7K shares |
Open market or private sale | 52.8K shares |